Skip to contentC
CNBX Pharmaceuticals Inc.
C
CNBXCNBX Pharmaceuticals Inc. Q3 2015 · 10-Q
Revenue$50.00K$50.00K— vs Q3 2014 Net Income-$26.48K-$26.48KN/M vs Q3 2014 EPS Diluted$0.00$0.00N/M vs Q3 2014 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
CNBX Pharmaceuticals Inc. · CIK 1343009 · Engraved from SEC EDGAR
-$13,845
N/M
Operating Cash Flowderived$11,105−19.1% Free Cash Flowderived$11,105−19.1% Margins · derivedGross margin100.0%
Operating margin-27.7%
Net margin-53.0%
ended May 31, 2016 · filed Jul 13, 2016 · 43 d after period end